Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells

Reproductive Biology and Endocrinology

Volumn 1, Issue , 2003, Pages

  Luo, Xiaoping ^a   Xu, Jingxia ^a,b   Chegini, Nasser ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GONADORELIN DERIVATIVE; ITURELIX; LEUPRORELIN; MESSENGER RNA; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; ANTISENSE OLIGODEOXYNUCLEOTIDE; DNA BINDING PROTEIN; GONADORELIN; HORMONE ANTAGONIST; OLIGOPEPTIDE; PROTEIN SERINE THREONINE KINASE; SMAD3 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; SMAD7 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CELL TYPE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CELL; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; PARACRINE SIGNALING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; ADULT; BIOSYNTHESIS; CELL CULTURE; CULTURE MEDIUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADULT; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LEUPROLIDE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGOPEPTIDES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; STROMAL CELLS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 4344657836     PISSN: 14777827     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7827-1-125     Document Type: Article

References (61)

1. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N: A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res 2000, 26:325-331.
2. Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S: Regression of endometrial hyperplasia after treatment with the gonadotrophin- releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999, 14:479-484.
3. Burton JL, Wells M: Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998, 33:297-303.
4. Devroey P, Pados G: Preparation of endometrium for egg donation. Hum Reprod Update 1998, 4:856-861.
5. Hernandez ER: Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000, 15:1211-1216.
6. Kol S: Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? Hum Reprod 2000, 15:1881-1882.
7. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R: The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2000, 8:279-290.
8. Bourgain C, Ubaldi F, Tavaniotou A, Smitz J, Van Steirteghem AC, Devroey P: Endometrial hormone receptors and proliferation index in the periovulatory phase of stimulated embryo transfer cycles in comparison with natural cycles and relation to clinical pregnancy outcome. Fertil Steril 2002, 78:237-244.
9. Chegini N, Rong H, Dou Q, Kipersztok S, Williams RS: Gonadotropin releasing hormone (GnRH) and GnRH receptor gene expression in human myometrial and leiomyomta and the direct action of GnRH analogs on myometrial smooth muscle cells interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 1996, 81:3215-3221.
10. Raga F, Casan EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML: Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998, 59:661-669.
11. Dong KW, Marcelin K, Hsu MI, Chiang CM, Hoffman G, Roberts JL: Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue. Mol Hum Reprod 1998, 4:893-898.
12. Cheon KW, Lee HS, Parhar IS, Kang IS: Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle. Mol Hum Reprod 2001, 7:447-452.
13. Grundker C, Gunthert AR, Millar RP, Emons G: Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002, 87:1427-1430.
14. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N: Suppression of TGF-βs and TGF-βs receptors mRNA and protein expression in leiomyomata in women receiving gonadotropin releasing hormone agonist therapy. J Clin Endocrinol Metab 1996, 81:3222-3230.
15. Dou Q, Tarnuzzer RW, Williams RS, Schultz GS, Chegini N: Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod 1997, 3:1005-1014.
16. Vignali M: Molecular action of GnRH analogues on ectopic endometrial cells. Gynecol Obstet Invest 1998, 45(Suppl 1):2-5.
17. Raga F, Casan EM, Wen Y, Huang HY, Bonilla-Musoles F, Polan ML: Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab 1999, 84:636-642.
18. Imai A, Takagi A, Tamaya T: Gonadotropin-releasing hormone analog repairs reduced endometrial cell apoptosis in endometriosis in vitro. Am J Obstet Gynecol 2000, 182:1142-1146.
19. Grundker C, Schlotawa L, Viereck V, Emons G: a Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin. Eur J Endocrinol 2001, 145:651-658.
20. Grundker C, Volker P, Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein a (I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001, 142:2369-2380.
21. Chegini N, Tang XM, Ma C, Williams RS: The effects of gonadotropin releasing hormone analogues, add-back, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cells growth and transforming growth factor beta expression. Mol Hum Reprod 2002, 12:1071-1078.
22. Tang XM, Zhao Y, Rossi MJ, Abu-Rustum RS, Ksander GA, Chegini N: Expression of transforming growth factor-beta (TGF β) isoforms and TGF β type II receptor messenger ribonucleic acid and protein, and the effect of TGF βs on endometrial stromal cell growth and protein degradation in vitro. Endocrinology 1994, 35:450-459.
23. Casslen B, Sandberg T, Gustavsson B, Willen R, Nilbert M: Transforming growth factor beta1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1. Biol Reprod 1998, 58:1343-1350.
24. Sandberg T, Casslen B, Gustavsson B, Benraad TJ: Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis. Biol Reprod 1998, 59:759-767.
25. Ma C, Chegini N: Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-β1. Mol Hum Reprod 1999, 10:950-954.
26. Chegini N, Williams RS: Implication of growth factor and cytokine networks in endometrium. In Cytokines in human reproduction (Edited by: Hill J). Wiley & Sons Publisher. New York 2000, 92-132.
27. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358.
28. Chegini N, Gold LI, Williams RS: Localization of transforming growth factor beta isoforms TGF-β1, TGF-β2, and TGF-β3 in surgically induced endometriosis in the rat. Obstet Gynecol 1994, 83:455-461.
29. Oosterlynck DJ, Meuleman C, Waer M, Koninckx PR: Transforming growth factor-beta activity is increased in peritoneal fluid from women with endometriosis. Obstet Gynecol 1994, 83:287-292.
30. Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI: Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 1994, 54:2347-2358.
31. Bruner KL, Rodgers WH, Gold LI, Korc M, Hargrove JT, Matrisian LM, Osteen KG: Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci USA 1995, 92:7362-7366.
32. Lea RG, Underwood J, Flanders KC, Hirte H, Banwatt D, Finotto S, Ohno I, Daya S, Harley C, Michel M: A subset of patients with recurrent spontaneous abortion is deficient in transforming growth factor beta-2-producing "suppressor cells" in uterine tissue near the placental attachment site. Am J Reprod Immunol 1995, 34:52-64.
33. Dennler S, Goumans MJ, ten Dijke P: Transforming growth factor beta signal transduction. J Leukoc Biol 2002, 71:731-740.
34. Luo X, Xu J, Chegini N: The expression of Smads in human endometrium and regulation and induction in endometrial epithelial and stromal cells by transforming growth factor-beta. J Clin Endocrinol Metab 2003, 88:4967-4976.
35. Yamada Y, Yamamoto H, Yonehara T, Kanasaki H, Nakanishi H, Miyamoto E, Miyazaki K: Differential activation of the luteinizing hormone {beta}-subunit promoter by activin and gonadotropin-releasing hormone: A role for the mitogen-activated protein kinase signaling pathway in L{beta}T2 gonadotrophs. Biol Reprod 2003.
36. Ellsworth BS, Burns AT, Escudero KW, Duval DL, Nelson SE, Clay CM: The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol Cell Endocrinol 2003, 206:93-111.
37. Norwitz ER, Xu S, Xu J, Spiryda LB, Park JS, Jeong KH, McGee EA, Kaiser UB: Direct binding of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene. J Biol Chem 2002, 277:37469-37478.
38. Norwitz ER, Xu S, Jeong KH, Bedecarrats GY, Winebrenner LD, Chin WW, Kaiser UB: Activin A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. Endocrinology 2002, 143:985-997.
39. Xu J, Luo X, Chegini N: Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 2003, 88:1350-1361.
40. Chegini N, Rossi MJ, Masterson BJ: Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and EGF and PDGF beta-receptors in human endometrial tissue: localization and in vitro action. Endocrinology 1992, 130:2373-2385.
41. Kraus S, Naor Z, Seger R: Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 2001, 32:499-509.
42. Leung PC, Cheng CK, Zhu XM: Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 2003, 202:145-153.
43. Millar RP: GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2002, 14:35-43.
44. Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P: Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 1998, 249:505-511.
45. Massague J, Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000, 19:1745-1754.
46. Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM, Dooley S: Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-β)-induced activation of Smad7. The TGF-β: response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J Biol Chem 2000, 275:29308-29317.
47. Garcia-Montero AC, Vasseur S, Giono LE, Canepa E, Moreno S, Dagorn JC, Iovanna JL: Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p38 gene expression. Biochem J 2001, 357:249-253.
48. Pouliot F, Labrie C: Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. Int J Cancer 1999, 81:98-103.
49. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M: Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999, 59:2731-2738.
50. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F: Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001, 276:42908-42914.
51. Ott TR, Troskie BE, Roeske RW, Illing N, Flanagan CA, Millar RP: Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist. Mol Endocrinol 2002, 16:1079-1088.
52. Sun YM, Flanagan CA, Illing N, Ott TR, Sellar R, Fromme B, Hapgood J, Sharp P, Sealfon SC, Millar RP: A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants. J Biol Chem 2001, 276:7754-7761.
53. Everest HM, Hislop JN, Harding T, Uney JB, Flynn A, Millar RP, McArdle CA: Signaling and antiproliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus. Endocrinology 2001, 142:4663-4672.
54. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP: Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 2001, 108:807-816.
55. Landstrom M, Heldin NE, Bu S, Hermansson A, Itoh S, ten Dijke P, Heldin CH: Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells. Curr Biol 2000, 10:535-538.
56. Chegini N, Kornberg L: Gonadotropin releasing hormone analogue (GnRHa) therapy alters signal transduction pathways involving MAP and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig 2003, 10:21-26.
57. Yue J, Mulder KM: Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem 2000, 275:30765-30773.
58. Zimmerman CM, Padgett RW: Transforming growth factor beta signaling mediators and modulators. Gene 2000, 249:17-30.
59. Scherer A, Graff JM: Calmodulin differentially modulates Smad1 and Smad2 signaling. J Biol Chem 2000, 275:41430-41438.
60. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S: Regulation of Smad signaling by protein kinase C. FASEB J 2001, 15:553-555.
61. Kretzschmar M, Doody J, Timokhina I, Massagué J: A mechanism of repression of TGFb/Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-816.